Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared on X:
“ALESIA Trial: Alectinib vs crizotinib in 1st line in Asian patients with ALK+ NSCLC. OS: NE alectinib vs 81 mo. crozotinib!! Yes with crizotinib. Difference not significant. What would be the CROWN trial (Lorlatinib vs Crizo) if comparator was alectinib?”
